4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop

2025-12-19 09:00:00 ET

Investment Overview - Update Since My Last Note On 4D-150

The last time I updated on the Emeryville, California-based genetic medicine specialist 4D Molecular Therapeutics ( FDMT ) it was early October 2024, and I made a bull case for the company's stock, based on the belief that the market had oversold it, in response to the latest data shared from Phase 2b and Phase 1/2a clinical studies of its lead candidate 4D-150, a gene therapy indicated for the treatment of the eye disease wet age-related macular degeneration (" Wet AMD")....

Read the full article on Seeking Alpha

For further details see: